Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3CMGM5
Fri, 16.08.2024
APONTIS PHARMA AG
Company Name:
APONTIS PHARMA AG
ISIN:
DE000A3CMGM5
Reason for the research:
Update
Recommendation:
BUY
from:
16.08.2024
Target price:
€17
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on APONTIS PHARMA AG (ISIN: DE000A3CMGM [ … ]
Mon, 24.06.2024
APONTIS PHARMA AG
First Berlin Equity Research on 24/06/2024 initiated coverage on APONTIS
PHARMA AG (ISIN: DE000A3CMGM5/ Bloomberg: APPH GR). Analyst Christian
Orquera placed a BUY rating on the stock, with a EUR 17.00 price target.
Abstract:
Apontis Pharma AG (Apontis) is a leading specialty pharmaceutical company
focusing on the development and marketing of a [ … ]
Wed, 08.05.2024
APONTIS PHARMA AG
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
Growth in revenue of Single Pill combinations to EUR 8.8 million in Q1 2024 (3M 2023: EUR 6.6 million), also due to a competitor’s temporary inability to supply products
Cooperation busines [ … ]
Fri, 05.04.2024
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) ha [ … ]
Tue, 06.02.2024
APONTIS PHARMA AG
APONTIS PHARMA successfully completes performance and efficiency improvement program
New go-to-market approach comes into action earlier than planned on 1 March 2024
Headcount reduced from 185 to 110 employees
Expenses at EUR 5.6 million at lower end of planning – no further burdens in financial year 2024
Savings – based on a full 12-month pe [ … ]
Thu, 09.11.2023
APONTIS PHARMA AG
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
Comprehensive program for achieving significant savings while increasing the effectiveness of sales and marketing presented
Savings of EUR 6.0 million to EUR 7.0 million expected over a [ … ]
Wed, 08.11.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
Monheim am Rhein, 8 November 2023. APONTIS PHARMA AG („Company“, Ticker APPH / ISIN DE000A3CMGM5) today based on the nine-month figures of the current financial year ann [ … ]
Thu, 10.08.2023
APONTIS PHARMA AG
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline
Single Pill revenue of EUR 12.1 million (6M 2022: EUR 17.7 million)
Atorimib down EUR 5.3 million due to ongoing supply bottlenecks – normalization as of November announced by supplier
Strong growth of Tonotec HCT (+41%) and Tonotec Lipid (+88%), Biramlo, Losamlo [ … ]
Mon, 31.07.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
Monheim am Rhein, 31 July 2023. APONTIS PHARMA AG („APONTIS PHARMA“ or the „Company“, Ticker APPH / ISIN DE000A3CMGM5) has been informed by AstraZeneca that the co-promotion [ … ]
Mon, 31.07.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
Monheim am Rhein, 31 July 2023. APONTIS PHARMA AG („APONTIS PHARMA“ or the „Company“, Ticker APPH / ISIN DE000A3CMGM5) has been informed by AstraZeneca that the co-promotion [ … ]